Sialidosis Market Size, Epidemiology, Leading Companies, Drugs and Competitive Analysis by DelveInsight
DelveInsight has launched a new report on "Sialidosis Market Insights, Epidemiology, and Market Forecast-2030".
DelveInsight's "Sialidosis
Market Insights, Epidemiology, and Market Forecast-2030" report
delivers an in-depth understanding of the Sialidosis , historical and
forecasted epidemiology as well as the Sialidosis market trends in the United
States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Sialidosis facts:
·
As per ISMRD, Sialidosis is among the rarest
Lysosomal Storage Diseases, affecting perhaps less than 1:4,000,000 worldwide
and is thought to be more common in people with Italian ancestry.
·
As per the International Advocate for
Glycoprotein Storage Diseases (ISMRD), Type I is the mildest form of
Sialidosis, with a range of onset from anywhere between 8-25 years of age.
·
According to NORD, Sialidosis affects males and
females in equal number.
·
The prevalence is estimated to be less than
1/1,000,000.
Request for Free
Sample Page: https://www.delveinsight.com/sample-request/sialidosis-market
View
Report: https://www.delveinsight.com/report-store/sialidosis-market
Scope of Sialidosis Report:
·
The report covers the descriptive overview of
Sialidosis , explaining its causes, signs and symptoms, pathophysiology,
diagnosis and currently available therapies
·
Comprehensive insight has been provided into the
Sialidosis epidemiology and treatment in the 7MM
·
Additionally, an all-inclusive account of both
the current and emerging therapies for Sialidosis are provided, along with the
assessment of new therapies, which will have an impact on the current treatment
landscape
·
A detailed review of Sialidosis market;
historical and forecasted is included in the report, covering drug outreach in
the 7MM
·
The report provides an edge while developing
business strategies, by understanding trends shaping and driving the global
Sialidosis market
Request for Free
Sample Page: https://www.delveinsight.com/sample-request/sialidosis-market
View
Report: https://www.delveinsight.com/report-store/sialidosis-market
Sialidosis
is characterized by a deficiency of the digestive enzyme, alpha-neuraminidase.
The lack of this enzyme results in an abnormal accumulation of complex
carbohydrates known as mucopolysaccharides, and of fatty substances known as
mucolipids. Both of these substances accumulate in bodily tissues. There are
four types of Sialidosis: Each type of Sialidosis is characterized by the age
of onset and by the type of physical and mental manifestations of this
disorder.
Type I is the mildest form of Sialidosis, with a range of
onset from anywhere between 8-25 years of age. Many of the characteristic
features of lysosomal storage diseases including coarse facial features,
hepatosplenomegaly (large liver and/or spleen), and dysostosis multiplex
(abnormal bone formation that is found in multiple bones of the body) are
absent.
One presenting feature is cherry red spots on ophthalmology
evaluation. Cherry red spots are spots on the retina that have storage of sugar
chain, causing the remainder of the healthy retina to look brighter. Other
presenting features include seizures, myoclonus (quick, non- rhythmic muscle
contractions that can occur in any skeletal muscle) and other symptoms of
nervous system dysfunction.
Type II Sialidosis has an earlier age of onset and more
severe symptoms than type I. The congenital form of type II Sialidosis has an
onset before birth and symptoms will be present in the newborn period. Often,
these babies have hydrops (accumulation of fluid in the body) and do not
survive the newborn period. Individuals that survive typically have mental
retardation and severe hepatosplenomegaly. Facial features are coarse and dysostosis
multiplex is present.
The infantile form of type II Sialidosis has an onset within
the first year of life. These individuals have mental retardation, coarse
facial features, dysostosis multiplex, and cherry red spots. Hepatosplenomegaly
may be present. Unique to the infantile type is renal involvement that may
range from structural to functional kidney problems.
Request for Sialidosis
Companies: https://www.delveinsight.com/sample-request/sialidosis-market
View
Report: https://www.delveinsight.com/report-store/sialidosis-market
Table of Contents:
1. Key Insights
2. Executive Summary
of Sialidosis
3. Competitive
Intelligence Analysis for Sialidosis
4. Sialidosis :
Market Overview at a Glance
5. Sialidosis :
Disease Background and Overview
6. Patient Journey
7. Sialidosis
Epidemiology and Patient Population
8. Treatment
Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of
Sialidosis Treatment
11. Marketed
Products
12. Emerging
Therapies
13. Sialidosis :
Seven Major Market Analysis
14. Attribute
analysis
15. 7MM: Market
Outlook
16. Access and
Reimbursement Overview of Sialidosis
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
Request for Detailed
TOC: https://www.delveinsight.com/sample-request/sialidosis-market
Related Reports:
- Hemophilia
B Market
- Filgrastim
Biosimilars
- France
Healthcare Market
- Polymyalgia
Rheumatica Market
- Sialidosis
Market
About DelveInsight
DelveInsight is a premier Business Consulting and Market
Research firm, focused exclusively on the life science segment. With a wide
array of smart end-to-end solutions, the firm helps the global Pharmaceutical,
Bio-Tech and Medical devices companies formulate prudent business decisions for
improving their performances to stay ahead of the competitors.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
Comments
Post a Comment